-
1
-
-
84855792427
-
Cancer statistics, 2012
-
Siegel R, Naishadham D, Hemal A. Cancer statistics, 2012. Ca Cancer J Clin 2012;62(1):10-29.
-
(2012)
Ca Cancer J Clin
, vol.62
, Issue.1
, pp. 10-29
-
-
Siegel, R.1
Naishadham, D.2
Hemal, A.3
-
2
-
-
84856610514
-
-
National Cancer Institute, Available at:, Accessed June 18, 2012
-
National Cancer Institute. Clinical trials search results. Available at: www.cancer. gov/cancertopics/types/prostate. Accessed June 18, 2012.
-
Clinical trials search results
-
-
-
3
-
-
0034694678
-
Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals
-
Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst 2000;92(24):2009-2017.
-
(2000)
J Natl Cancer Inst
, vol.92
, Issue.24
, pp. 2009-2017
-
-
Platz, E.A.1
Rimm, E.B.2
Willett, W.C.3
-
4
-
-
79958043675
-
-
(eds.), Bethesda, Md.: National Cancer Institute. Based on November 2011 SEER data submission. Updated August 20, Available at:, Accessed December 12, 2012
-
Howlader N, Noone AM, Krapcho M, et al. (eds.). SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, Md.: National Cancer Institute. Based on November 2011 SEER data submission. Updated August 20, 2012. Available at: http://seer.cancer. gov/csr/1975_2009_pops09. Accessed December 12, 2012.
-
(2012)
SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations)
-
-
Howlader, N.1
Noone, A.M.2
Krapcho, M.3
-
5
-
-
0842311632
-
The androgen axis in recurrent prostate cancer
-
Mohler JI, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440-448.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.2
, pp. 440-448
-
-
Mohler, J.I.1
Gregory, C.W.2
Ford III, O.H.3
-
6
-
-
57749087908
-
-
9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins
-
DeVita VT, Lawrence TS, Rosenberg SA. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology, 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011.
-
(2011)
DeVita, Hellman, and Rosenberg's Cancer: Principles and Practice of Oncology
-
-
DeVita, V.T.1
Lawrence, T.S.2
Rosenberg, S.A.3
-
7
-
-
51449087794
-
Targeting the androgen receptor pathway in prostate cancer
-
Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol 2008;8(4):440-448.
-
(2008)
Curr Opin Pharmacol
, vol.8
, Issue.4
, pp. 440-448
-
-
Chen, Y.1
Sawyers, C.L.2
Scher, H.I.3
-
9
-
-
79957497548
-
Expanding treatment options for metastatic prostate cancer
-
Antonarakis ES, Eisneberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364(21):2055-2058.
-
(2011)
N Engl J Med
, vol.364
, Issue.21
, pp. 2055-2058
-
-
Antonarakis, E.S.1
Eisneberger, M.A.2
-
10
-
-
4744366279
-
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
-
Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.
-
(2004)
N Engl J Med
, vol.351
, pp. 1502-1512
-
-
Tannock, I.F.1
de Wit, R.2
Berry, W.R.3
-
11
-
-
77953421580
-
-
Clinical Practice Guidelines: Prostate Cancer, version 3.2012
-
National Comprehensive Cancer Network. Clinical Practice Guidelines: Prostate Cancer, version 3.2012.
-
National Comprehensive Cancer Network
-
-
-
12
-
-
0842311632
-
The androgen axis in recurrent prostate cancer
-
Mohler JI, Gregory CW, Ford OH III, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10(2):440-448.
-
(2004)
Clin Cancer Res
, vol.10
, Issue.2
, pp. 440-448
-
-
Mohler, J.I.1
Gregory, C.W.2
Ford III, O.H.3
-
14
-
-
80052827038
-
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants
-
Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: Induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 2011;17:5913-5925.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5913-5925
-
-
Mostaghel, E.A.1
Marck, B.T.2
Plymate, S.R.3
-
16
-
-
77951523950
-
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy
-
Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010;28(9):1481-1488.
-
(2010)
J Clin Oncol
, vol.28
, Issue.9
, pp. 1481-1488
-
-
Ryan, C.J.1
Smith, M.R.2
Fong, L.3
-
17
-
-
84863791271
-
Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men
-
Acharya M, Bernard A, Gonzalez M, et al. Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemother Pharmacol 2012;69(6):1583-1590.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, Issue.6
, pp. 1583-1590
-
-
Acharya, M.1
Bernard, A.2
Gonzalez, M.3
-
18
-
-
77951518711
-
Significant and sustained antitumor activity in post-docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate
-
Reid AHM, Attard G, Danila DC, et al. Significant and sustained antitumor activity in post-docetaxel, castrationresistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-1495.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1489-1495
-
-
Reid, A.H.M.1
Attard, G.2
Danila, D.C.3
-
19
-
-
77951591066
-
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel treated castration-resistant prostate cancer
-
Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-1501.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1496-1501
-
-
Danila, D.C.1
Morris, M.J.2
de Bono, J.S.3
-
20
-
-
79957443342
-
Abiraterone and increased survival in metastatic prostate cancer
-
De Bono JS, Logothetis CJ, Molin A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995-2005.
-
(2011)
N Engl J Med
, vol.364
, pp. 1995-2005
-
-
de Bono, J.S.1
Logothetis, C.J.2
Molin, A.3
-
21
-
-
0020396015
-
Toxicity and response criteria of the Eastern Cooperative Oncology Group
-
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
-
(1982)
Am J Clin Oncol
, vol.5
, pp. 649-655
-
-
Oken, M.M.1
Creech, R.H.2
Tormey, D.C.3
-
22
-
-
0032747375
-
Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
-
Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgenindependent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999;17: 3461-3467.
-
(1999)
J Clin Oncol
, vol.17
, pp. 3461-3467
-
-
Bubley, G.J.1
Carducci, M.2
Dahut, W.3
-
23
-
-
84871048865
-
-
Available at:, Accessed June 29, 2012
-
Red Book online®. Available at: www. thomsonhc.com. Accessed June 29, 2012.
-
Red Book online®
-
-
|